Education
About Us
Working with TipRanks
Follow Us
Vera Therapeutics (VERA)
NASDAQ:VERA
VERA Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
VERA Stock 12 Month Forecast
Average Price Target
$70.60
▲(179.94% Upside)
| Highest Price Target$100.00 | Average Price Target$70.60 | Lowest Price Target$48.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
J.P. Morgan
$53→$52
Buy
106.19%
Upside
Reiterated
11/07/25
TD Cowen
$60
Buy
137.91%
Upside
Reiterated
11/06/25
Vera Therapeutics' Atacicept Shows Promising Phase 3 Results and Regulatory Progress, Earning Buy RatingWe believe today's data continues to show strong clinically meaningful results, and can support high commercial uptake for ataci on approval. Of note, there was no degradation of IgAN biomarker effect size from topline Ph2 ORIGIN2, suggesting eGFR data will also likely be similar to the excellent clinical benefit seen in Ph2. ORIGIN2, ataci showed stat sig separation on eGFR at 36 wks between 150mg pts and PBO, and add'l 96wk OLE data showed a mean annualized eGFR slope of -0.6 mL/min/year - a profile consistent with the general healthy population w/o disease.
LifeSci Capital
$70
Buy
177.56%
Upside
Reiterated
11/05/25
Vera Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy RatingThis morning, Vera Therapeucs (Nasdaq: VERA) reported Q3 2025 earnings, finishing the period with $497.4M in cash, cash equivalents, and marketable securies; the Company’s balance sheet along with the non-diluv e financing agreement with Oxford Finance is expected to fund operaons thr ough the commercial launch of atacicept. Recent updates from Vera’s pipeline include: Primary endpoint results from the ORIGIN 3 study (we expect addional data on paen t subgroups, Gd-IgA1, and hematuria) will be presented as a featured late-breaking oral presentaon during the opening plenary session of ASN Company also plans to host an investor webcast tomorrow at 4:30pm ET to review the data. As a reminder, treatment with 150mg QW atacicept (BLyS/APRIL inhibitor) led to a 46% absolute and 42% placebo-adjusted (P<0.0001) reducon from baseline in proteinuria at the pivotal study (our note HERE).
Cantor Fitzgerald
$100
Buy
296.51%
Upside
Reiterated
10/13/25
Evercore ISI
$75
Buy
197.38%
Upside
Reiterated
10/06/25
H.C. Wainwright
$75→$85
Buy
237.03%
Upside
Reiterated
08/06/25
Wolfe Research
―
Hold
―
Downgraded
08/04/25
Guggenheim
$65→$56
Buy
122.05%
Upside
Reiterated
07/01/25
Wedbush
$32→$23
Hold
-8.80%
Downside
Reiterated
06/09/25
Raymond James
$73
Buy
189.45%
Upside
Reiterated
06/06/25
Wells Fargo
$70
Buy
177.56%
Upside
Assigned
06/02/25
Scotiabank
$55→$65
Buy
157.73%
Upside
Reiterated
06/02/25
Jefferies
$57
Buy
126.01%
Upside
Assigned
06/02/25
Goldman Sachs
$58
Buy
129.98%
Upside
Reiterated
02/14/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
J.P. Morgan
$53→$52
Buy
106.19%
Upside
Reiterated
11/07/25
TD Cowen
$60
Buy
137.91%
Upside
Reiterated
11/06/25
Vera Therapeutics' Atacicept Shows Promising Phase 3 Results and Regulatory Progress, Earning Buy RatingWe believe today's data continues to show strong clinically meaningful results, and can support high commercial uptake for ataci on approval. Of note, there was no degradation of IgAN biomarker effect size from topline Ph2 ORIGIN2, suggesting eGFR data will also likely be similar to the excellent clinical benefit seen in Ph2. ORIGIN2, ataci showed stat sig separation on eGFR at 36 wks between 150mg pts and PBO, and add'l 96wk OLE data showed a mean annualized eGFR slope of -0.6 mL/min/year - a profile consistent with the general healthy population w/o disease.
LifeSci Capital
$70
Buy
177.56%
Upside
Reiterated
11/05/25
Vera Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy RatingThis morning, Vera Therapeucs (Nasdaq: VERA) reported Q3 2025 earnings, finishing the period with $497.4M in cash, cash equivalents, and marketable securies; the Company’s balance sheet along with the non-diluv e financing agreement with Oxford Finance is expected to fund operaons thr ough the commercial launch of atacicept. Recent updates from Vera’s pipeline include: Primary endpoint results from the ORIGIN 3 study (we expect addional data on paen t subgroups, Gd-IgA1, and hematuria) will be presented as a featured late-breaking oral presentaon during the opening plenary session of ASN Company also plans to host an investor webcast tomorrow at 4:30pm ET to review the data. As a reminder, treatment with 150mg QW atacicept (BLyS/APRIL inhibitor) led to a 46% absolute and 42% placebo-adjusted (P<0.0001) reducon from baseline in proteinuria at the pivotal study (our note HERE).
Cantor Fitzgerald
$100
Buy
296.51%
Upside
Reiterated
10/13/25
Evercore ISI
$75
Buy
197.38%
Upside
Reiterated
10/06/25
H.C. Wainwright
$75→$85
Buy
237.03%
Upside
Reiterated
08/06/25
Wolfe Research
―
Hold
―
Downgraded
08/04/25
Guggenheim
$65→$56
Buy
122.05%
Upside
Reiterated
07/01/25
Wedbush
$32→$23
Hold
-8.80%
Downside
Reiterated
06/09/25
Raymond James
$73
Buy
189.45%
Upside
Reiterated
06/06/25
Wells Fargo
$70
Buy
177.56%
Upside
Assigned
06/02/25
Scotiabank
$55→$65
Buy
157.73%
Upside
Reiterated
06/02/25
Jefferies
$57
Buy
126.01%
Upside
Assigned
06/02/25
Goldman Sachs
$58
Buy
129.98%
Upside
Reiterated
02/14/25
Best Analysts Covering Vera Therapeutics
1 Month
xxx
Success Rate
13/22 ratings generated profit
Average Return
+5.64%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 59.09% of your transactions generating a profit, with an average return of +5.64% per trade.
3 Months
xxx
Success Rate
11/19 ratings generated profit
Average Return
+36.02%
reiterated a xxx
rating 18 hours ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +36.02% per trade.
1 Year
Success Rate
11/19 ratings generated profit
Average Return
+81.82%
reiterated a buy rating 18 hours ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +81.82% per trade.
2 Years
xxx
Success Rate
14/22 ratings generated profit
Average Return
+68.54%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +68.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
VERA Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
28
22
9
11
8
Buy
0
0
1
1
1
Hold
2
2
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
24
11
13
9
Each month's total comprises the sum of three months' worth of ratings.
VERA Financial Forecast
VERA Stock Forecast FAQ
What is VERA’s average 12-month price target, according to analysts?
Based on analyst ratings, Vera Therapeutics’s 12-month average price target is 70.60.
What is VERA’s upside potential, based on the analysts’ average price target?
Vera Therapeutics has 179.94% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is VERA a Buy, Sell or Hold?
Vera Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Vera Therapeutics’s price target?
The average price target for Vera Therapeutics is 70.60. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $48.00. The average price target represents 179.94% Increase from the current price of $25.22.
The highest analyst price target is $100.00 ,the lowest forecast is $48.00. The average price target represents 179.94% Increase from the current price of $25.22.
What do analysts say about Vera Therapeutics?
Vera Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of VERA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.